Research Programs

Infectious Diseases

To identify host- and parasite-specific biomarker(s) present in human subjects with viable adult females of Onchocerca volvulus (Ov) and to develop and configure rapid point of care methods to detect (or sense) these biomarkers.

Infectious Diseases

SHORTEN-TB will build on lessons learned from the HIT-TB program to identify leads that have the greatest potential to comprise drug regimens that will significantly reduce the duration of chemotherapy for tuberculosis.

Infectious Diseases

SHORTEN-TB will build on lessons learned from the HIT-TB program to identify leads that have the greatest potential to comprise drug regimens that will significantly reduce the duration of chemotherapy for tuberculosis.

Infectious Diseases

The project provides the FNIH management and advisory services for research programs seeking to develop new cost-effective and sustainable biologic strategies for controlling mosquito-borne infections like malaria and dengue fever.

Infectious Diseases

In response to the critical Ebola Virus Disease (EVD) outbreak in 2014, the FNIH has established a fund that supports the Division of Clinical Research of the National Institute of Allergy and Infectious Diseases (NIAID) in its efforts to prevent, treat and research the EVD in West Africa.

Infectious Diseases

As a subset of activities under the VCTR program, the New Insecticides for Malaria Control program addressed the urgent need for new chemicals to kill mosquitoes that transmit malaria.

Infectious Diseases

This program supports research to develop new biologic and chemical strategies to control disease transmission by vector mosquitoes.

Neurodegenerative Disorders

The Accelerating Medicines Partnership Alzheimer’s Disease Project (AMP-AD) is a precompetitive partnership among government, industry, and nonprofit organizations that focuses on discovering novel, clinically relevant therapeutic targets and on developing biomarkers to help validate existing therapeutic targets. 

Neurodegenerative Disorders

In 2016, the AMP Executive Committee approved the planning of an AMP effort to confront the challenges presented by Parkinson’s disease (PD). This complements current efforts in the areas of Alzheimer’s disease, type 2 diabetes and the autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus). A critical component of this partnership is that all members have agreed to make the AMP Parkinson’s disease (AMP PD) data and analyses publicly available to the broad biomedical community.

Neurodegenerative Disorders

ADNI was established to facilitate the development of effective treatments for Alzheimer’s disease by validating biomarkers for clinical trials and determining the relationships between the clinical, cognitive, imaging, genetic, and biochemical biomarker characteristics of AD.